PRTN3 and arthritic joint disease: Although the trial failed to demonstrate a reduction in progression from the clinically suspect arthralgia stage to clinical arthritis, data from a post hoc analysis recently presented at the EULAR Congress 2024 showed that the greatest benefit of a very early intervention with methotrexate in order to prevent RA development might be particularly evident in ACPA-negative subjects [49].